---
layout: minimal-medicine
title: Fondaparinux
---

# Fondaparinux
### Generic Name
Fondaparinux

### Usage
Fondaparinux is a type of anticoagulant medication, specifically a factor Xa inhibitor.  Its primary use is in preventing blood clots (thrombosis), particularly deep vein thrombosis (DVT) in patients undergoing certain surgeries. These surgeries include hip fracture surgery, hip replacement, knee replacement, and abdominal surgery.  It's also used to treat DVT and acute pulmonary embolism (PE), often in conjunction with warfarin.  Importantly, Fondaparinux can be used in patients with heparin-induced thrombocytopenia (HIT), a serious complication of heparin treatment.  While its primary use is within these contexts, there are off-label uses in managing acute coronary syndrome and certain types of superficial vein thrombosis, which should only be considered under the guidance of a physician.


### Dosage
Dosage varies greatly depending on the condition being treated, the patient's weight, and the method of administration (subcutaneous injection is most common).  Precise instructions must be followed as directed by a healthcare professional. There is no established pediatric dosage.  Here are some examples of dosage guidelines; these are *not* exhaustive and should not be used for self-medication:

* **Treatment of DVT and PE:**  Subcutaneous injection. Dosage is based on weight:  <50 kg (5 mg daily), 50-100 kg (7.5 mg daily), >100 kg (10 mg daily).  The duration of treatment is determined by the individual patient's needs and risk factors and ranges from several months to longer depending on the circumstances.

* **Prophylaxis of DVT (surgery):** Subcutaneous injection.  The typical dose is 2.5 mg daily, starting after surgery (6-8 hours post-op). The duration varies depending on the surgery type and patient's mobility, ranging from several days to several weeks. For major abdominal or pelvic surgery, extending therapy to up to 4 weeks may be considered.

* **Heparin-induced thrombocytopenia (HIT):** Subcutaneous injection, dosing is similar to DVT/PE treatment. Duration of therapy depends on presence or absence of thrombosis, generally ranging from 4 weeks to 6 months.

* **Off-label uses:** Dosage varies considerably based on the specific condition and physician’s judgement. For example, in acute coronary syndrome, the dosage may range from 2.5mg daily to IV administration followed by subcutaneous injections.


### Side Effects
Common side effects can include:

* Anemia
* Hematoma (bruising)
* Bleeding (minor or major)
*  Increased wound secretion/skin blister (especially after surgery)
* Nausea
* Dizziness
* Insomnia

Less common, but more serious side effects include:

* Thrombocytopenia (low platelet count)
* Spinal or epidural hematoma (bleeding around the spinal cord, potentially leading to paralysis)
* Allergic reactions (anaphylaxis)
* Severe bleeding

It is crucial to contact a healthcare provider immediately if any serious side effects or unusual symptoms develop.

### How it Works
Fondaparinux works by selectively inhibiting factor Xa, a crucial enzyme in the blood clotting cascade.  This inhibition prevents the formation of thrombin, which is essential for the formation of blood clots. By reducing factor Xa activity, Fondaparinux helps prevent the development of DVT, PE, and other thrombotic events.  It does this in a targeted way, minimizing the risk of excessive bleeding compared to some other anticoagulants.

### Precautions
* **Contraindications:** Fondaparinux is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), active major bleeding, certain types of thrombocytopenia, and severe hypersensitivity to the medication.  It’s also contraindicated for DVT prophylaxis in patients weighing less than 50 kg.

* **Interactions:**  Concurrent use with other anticoagulants (heparin, warfarin, etc.), antiplatelet agents, or medications that affect hemostasis increases the risk of bleeding.

* **Renal and Hepatic Impairment:**  Dosage adjustments may be necessary for patients with mild to moderate renal impairment. Patients with severe renal or hepatic impairment should be carefully monitored.

* **Pregnancy and Breastfeeding:**  The use of Fondaparinux during pregnancy and breastfeeding is generally avoided unless the benefits outweigh the potential risks to the mother and child.

* **Spinal/Epidural Hematomas:** There's an increased risk of spinal or epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture while taking Fondaparinux. Close monitoring for neurological symptoms is essential.

* **Monitoring:** Regular blood tests (CBC, platelet count, creatinine) may be needed to monitor blood clotting and kidney function.


### FAQs

* **Q: Can I stop taking Fondaparinux if I feel better?** A: No, never stop taking Fondaparinux without consulting your doctor.  Stopping prematurely can increase the risk of blood clots.

* **Q: What should I do if I miss a dose?** A: Contact your doctor or pharmacist immediately for instructions.  Do not double the dose.

* **Q: How should I store Fondaparinux?** A: Store Fondaparinux as directed on the label, typically at room temperature, away from light and moisture.

* **Q: Are there any dietary restrictions while taking Fondaparinux?** A: No specific dietary restrictions are usually associated with Fondaparinux, but maintaining a healthy diet and lifestyle is always beneficial.

* **Q: What should I do if I experience bleeding?** A:  Contact your doctor or seek immediate medical attention if you experience any unusual or excessive bleeding.


**Disclaimer:** This information is intended for educational purposes only and does not constitute medical advice.  Always consult with a healthcare professional before starting, stopping, or changing any medication.  The information provided here may not be exhaustive, and specific dosages and precautions may vary based on individual patient needs and the specific formulation of Fondaparinux. Always refer to the official prescribing information for the most accurate and up-to-date details.
